ATCC’s headquarters became the epicenter of America’s biotech future when the NSCEB brought its national roadshow to Virginia. With policymakers, scientists, national security leaders, and industry executives packed shoulder-to-shoulder, the Commission’s warning came through clearly: the U.S. has a shrinking window to out-innovate global competitors, and trusted scientific infrastructure will determine who wins the next century.
That urgency set the tone for a panel that cut straight to the core of the issue—how authenticated inputs and trusted materials underpin every pillar of the modern bioeconomy. What unfolded was a frank, multidimensional conversation — spanning supply-chain vulnerabilities, emerging biomanufacturing models, AI-driven biology, and the sobering national-security risks of falling behind.
Retired Army Colonel Victor Suarez, Founder, BluZone Bioscience & Supply Chain Solutions and recently appointed ATCC Board member, opened the conversation with a message that landed like a warning flare. Authenticated inputs—materials, data, cell lines, starting chemicals—are not administrative niceties, he argued. They are “strategic and critical national infrastructure” in a world where adversaries exploit biological supply chains and AI models are only as trustworthy as the data fed into them. The consequences of unauthenticated inputs, he said, range from scientific irreproducibility to regulatory failures to vulnerabilities that can be weaponized in public health or biodefense.
That framing—a blend of technical precision and national-security gravity—set the tone for what became a strikingly urgent conversation.
A Supply Chain in Crisis, and a Warning from the Future
The first voice to speak was Dr. Eric Edwards, CEO of Phlow Corp, whose frontline vantage point on America’s pharmaceutical supply chain left the audience visibly unsettled. The U.S., he said, has lost domestic manufacturing capability so dramatically that many essential medicines have not been produced onshore “for decades.” China now holds “a predominant position” in key pharmaceutical inputs, from starting materials to active ingredients.
Edwards shared something rarely acknowledged in public forums: the U.S. doesn’t fully know where many of its drug ingredients originate. Traceability is broken. Systems are paper-based. Chain-of-custody is weak. And adversaries—or simply bad actors—could exploit these weaknesses long before regulators detect a problem.
His message was unambiguous:
If biotech does not learn from the collapse of small-molecule supply chains, the same crisis will hit biologics, biosimilars, and advanced therapeutics.
And the costs will be far greater.
The panel grew quiet when he added, “The deeper we got into the supply chain, the more we realized we’re in trouble—and far worse than we imagined.”
A National Security Reality Check
If Edwards laid out the economic and infrastructural risks, NSCEB Commissioner Dawn Meyerriecks delivered the geopolitical ones. With decades of senior leadership in the intelligence community, she spoke with the clarity of someone who has seen examples up close of how biology can be used—not theoretically, but operationally.
She described scenarios that foreign partners themselves had raised: What happens if a nation becomes dependent on a rival’s biological supply chain? What if adversaries control access to food, vaccines, or even seeds? “If you can conceive of it,” she cautioned, “someone out there is trying to do it.”
Her point was stark: America’s adversaries do not share its guardrails, values, or constraints. And biology—more accessible, more digitized, more globally interconnected than ever—is now a domain where strategic advantage can be built quietly and exploited quickly.
It became clear why the Commission insists on urgency. This is not abstract policy. It is a race.
Engineering Biology for a New Era — If the Inputs Can Be Trusted
If the first half of the discussion centered on risk, the second turned toward the opportunities—and the technical breakthroughs—that could propel U.S. biotech leadership, provided authenticity and traceability keep pace.
Dr. Andrew Magyar, founder of Capra Biosciences, explained how modern biomanufacturing can decouple feedstocks from outputs—a powerful advantage over traditional petrochemistry. His team is developing systems capable of using multiple feedstocks, from agricultural waste to glycerol, to produce consistent high-value outputs. It’s a technological leap that makes biomanufacturing resilient, sustainable, and less dependent on single global suppliers.
Through partnerships with DARPA and ATCC, Capra is building strains and processes that will become shared national assets—deposited at ATCC to ensure broad access, validation, and reproducibility.
This is where the panel’s central theme sharpened: without authenticated biological inputs—strains, DNA constructs, datasets—the entire AI and automation revolution in biotech collapses.
Dr. Patrick Boyle, ATCC’s interim CSO and a pioneer in synthetic biology, made this point vividly. AI progress in biology is limited not by compute, he argued, but by trusted, well-labeled datasets. Today’s biological data landscape is too noisy, inconsistent, and incorrectly attributed for AI models to truly understand or engineer living systems. “Even big pharma has cell lines in freezers that don’t match what others call the same cell line,” he said. And most of the scientific literature, he noted, is unvalidated.
Authenticated inputs aren’t just helpful—they are the enabling substrate of the next era of biotechnology.
Opening the Microbial Black Box
Few captured the imagination of the room like Dr. Nili Ostrov, CSO of Cultivarium, who is building the world’s first Focused Research Organization (FRO) dedicated to unlocking non-model organisms. Most of biotechnology, she reminded the audience, is built on a handful of microbes like E. coli—not because they’re the best, but because they were the first we learned to work with.
Nature holds millions of organisms that could be invaluable for biomanufacturing, sustainability, and biosecurity—but they remain inaccessible because we don’t yet know how to grow, engineer, or characterize them.
Her vision: create the tools, workflows, and data standards to make new organisms as accessible as the model ones—and ensure that everything begins with validated, traceable biological material. “The first thing we did as a startup,” she said, “was talk to Ruth and ATCC. Because some things you shouldn’t innovate on. Reliable source material is one of them.”
A Blueprint That Won’t Build Itself
As the discussion neared its end, Suarez asked the question that lingered over the entire event: what are the headwinds?
Meyerriecks answered with characteristic bluntness. The biggest challenge is not technology—it is will. The country is flooded with noise, she said. Issues rise and fall in the news cycle before anyone can distinguish hype from real threat. “This can’t be a one-and-done,” she warned. Sustained pressure, education, and cross-sector coordination are needed—long before a national crisis forces action.
The Virginia Playbook — How Industry Led, and Government Catalyzed
When Dr. Eric Edwards described how Virginia built one of the nation’s fastest-growing advanced pharmaceutical manufacturing hubs, he offered a blueprint the entire bioeconomy can learn from. It didn’t start with government—it started with industry alignment.
Leaders from Phlow, AMPAC, major pharma companies, community colleges, universities, and workforce organizations came together to form the Alliance for Building Better Medicines—a 55-member coalition spanning 11 academic partners, 6 government entities, 13 industry organizations, and 10 workforce groups.
With a unified strategy already in hand, they went to state and federal partners and secured a $53 million Build Back Better Regional Challenge Award, which catalyzed:
- 2,000+ permanent advanced manufacturing jobs
- 12,800 construction jobs
- A 90,000 sq. ft. training center backed by $120M from big pharma
- New facilities from Merck, AstraZeneca, and Lilly
Edwards’ message was clear:
“The government is not going to solve this for us… We’re in charge of the strategy. Then you present it to the government, and then they can get behind it.”
For regions trying to build bioindustrial capacity, the Virginia model offers a simple playbook: align industry first, build the roadmap second, bring government in third.
The lesson was clear: ecosystems don’t emerge—they are built. Together.
And the bioindustrial sector, the panel agreed, can replicate this model nationwide—if leaders stop waiting for government direction and begin presenting government with aligned, actionable strategies.
The Bioeconomy’s Strength Depends on Its Inputs — and Its Unity
Across every perspective—security, manufacturing, research, AI, entrepreneurship—the message converged:
Authenticated inputs are not a technical detail. They are the backbone of a secure, scalable, globally competitive bioeconomy.
Without them, AI models fail.
Biomanufacturing becomes vulnerable.
Supply chains collapse.
Innovation stalls.
Adversaries exploit openings.
And the U.S. risks repeating the mistakes that hollowed out its pharmaceutical base.
With them, America has a chance—not just to compete, but to lead.
The panel closed with a feeling not of fear, but of resolve. These leaders made it clear that the foundation of U.S. biotechnology will be shaped now—by the choices made in rooms like this one, by the alliances built, and by the shared understanding that the age of biology will reward those who prepare early and consistently.
The window is open.
But not for long.
And as the panelists made clear, the race for biotechnology leadership will be won or lost at the level of the inputs, the trust we build into our systems, and the unity we choose to pursue.
